|
Overview
Introduction
Scope
Report Highlights
Reasons to Purchase
DRIVERS AND TRENDS
No new drugs have been approved for the treatment of multiple
myeloma in two decades, leaving physicians using non-pharmacological means to
improve efficacy of treatment. Consequently, physicians are eagerly awaiting the
new generation of biotechnology manufacturerfs drugs. Celgenefs Thalomid,
Aventis' Genasense and Millenniumfs Velcade will be the first market entrants,
but high volume use still awaits subsequent market entrants.
INTRODUCTION TO MULTIPLE MYELOMA
An overview of the patient pathway to treatment, including
disease pathology, presentation patterns, diagnosis and staging, enabling the
reader to understand the factors that affect the hematologists treatment options
and prescribing decisions.
TREATMENT STRATEGIES
Analysis of the treatment strategies used for the management
of multiple myeloma, including an analysis of the currently used drugs and drug
regimens, providing a benchmark for the assessment of pipeline agents.
HOT TOPICS IN MULTIPLE MYELOMA
Discussion and analysis of the hot topics within the
physician community presented at this years leading oncology conferences,
including the ASH (American Society of Hematology), ASCO (American Society of
Clinical Oncology), UICC (Union Internationale Contre le Cancer) and ESMO
(European Society for Medical Oncology) conferences.
- Autologous stem cell transplantation
- High-dose Therapy in multiple myeloma
- Proteasome inhibitors
- Bisphosphonates
PIPELINE ANALYSIS
An overview of the agents in clinical development for
multiple myeloma, including an in-depth analysis of phase III pipeline agents
and the most recent updates from the ASH conference.
- Thalomid (thalidomide)
- Doxil/Caelyx (liposomal doxorubicin)
- Genasense
- Velcade
- Skeletal Targeted Radiotherapy (STR)
MARKET FORECASTS
Forecast of pipeline multiple myeloma drug sales, including
two scenario-based forecasts.
DATASETS
- Table 1: Key metrics for the multiple myeloma drugs market, 2002, 2006 and
2010
- Table 2: Staging classification of the Memorial Sloan Kettering Cancer
Center staging system for multiple myeloma
- Table 3: Incidence of pancreatic cancer in the seven major markets,
2002-2010
- Table 4: Drugs in development for multiple myeloma, 2002
- Table 5: Breakdown of forecast revenue for the key late stage product for
multiple myeloma, 2002-2010
- Table 6: Forecast revenues for key multiple myeloma pipeline agents in the
event of adverse publicity for Thalomid upon launch, 2002-2010
- Table 7: Forecast revenues for key multiple myeloma pipeline agents in the
event of advances in ASCT, 2002-2010
- Figure 1: Incidence of pancreatic cancer in the seven major markets,
2002-2010
- Figure 2: SWOT analysis of Thalomid
- Figure 3: SWOT analysis of Doxil/Caelyx
- Figure 4: SWOT analysis for Genasense
- Figure 5: SWOT analysis of Velcade
- Figure 6: SWOT analysis of STR
- Figure 7: Performance of key multiple myeloma pipeline drugs, 2002-2010
- Figure 8: Forecast revenues for key multiple myeloma pipeline agents in
the event of adverse publicity for Thalomid upon launch, 2002-2010
- Figure 9: Forecast revenues for key multiple myeloma pipeline agents in
the event of advances in ASCT, 2002-2010
| 
View Cart
